3rd Quarter - Report

DENDREON PHARMACEUTICALS, LLC for DENDREON PHARMACEUTICALS, LLC

Firm
Client
Income
—
Expenses
$102,780
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Medicare Part B drug payment reform. Specifically, access to autologous cellular immunotherapies in Medicare Part B Access to Prostate Cancer Treatment Monitoring the FY 2022 Appropriations and Reconciliation Process. Provisions included in Title I - Subtitle B of PL. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.

Foreign entity interest: Dendreon, a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.

LobbyistCovered position, as disclosed
ANDREW SAELENS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.